公开(公告)号：US20250101074A1

公开(公告)日：2025-03-27

申请号：US18790379

申请日：2024-07-31

Applicant: AFFIBODY AB

Inventor： Fredrik Frejd ,  Joachim Feldwisch ,  Susanne Klint ,  Lindvi Gudmundsdotter

IPC: C07K14/54 ,  A61K38/00 ,  A61K38/20 ,  C07K14/745

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX2DX4AX6X7EIX10X11LPNL X16X17X18QX20X21AFIX25 X26LX28X29. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.

公开(公告)号：USRE49495E1

公开(公告)日：2023-04-18

申请号：US16840882

申请日：2020-04-06

Applicant: Affibody AB

Inventor： Erik Nordling ,  Joakim Nilsson ,  Patrik Strömberg

IPC: C07K14/00 ,  C07K1/04 ,  C07K14/31 ,  C12Q1/6874 ,  G01N33/68

Abstract: The present disclosure relates to a class of engineered polypeptides and provides a polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55). The present disclosure also relates to populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the amino acid sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55), and methods for selecting a desired polypeptide having an affinity for a predetermined target from said population.

公开(公告)号：US20220411743A1

公开(公告)日：2022-12-29

申请号：US17772808

申请日：2020-11-09

Applicant: Affibody AB

Inventor： Finn Dunås ,  Belinda Röjstäter ,  Tomas Moks

IPC: C12M1/00 ,  C12N1/06 ,  C07K1/14

Abstract: A method of extracting a cytoplasmic or periplasmic protein. The method comprises provision of a first cell suspension comprising cells, the cells containing a cytoplasmic or periplasmic protein of interest to be extracted, the first cell suspension having a first temperature, and heating of the first cell suspension to an operating temperature, at which operating temperature at least a fraction of the cells is subject to heat-induced lysis and at least a fraction of the cytoplasmic or periplasmic protein of interest to be extracted is not subject to irreversible denaturation. The heating of the first cell suspension comprises provision of an aqueous solution, the aqueous solution having a second temperature that is higher than the first temperature, and mixing of the first cell suspension with the aqueous solution, thereby obtaining a second cell suspension, the second cell suspension having a third temperature that is higher than the first temperature. A system for extracting a cytoplasmic or periplasmic protein. The system comprises, i.a., a static mixer.

公开(公告)号：US20220389066A1

公开(公告)日：2022-12-08

申请号：US17771307

申请日：2020-11-05

Applicant: Affibody AB

Inventor： Elisabet Wahlberg

IPC: C07K14/435 ,  C07K19/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for high mobility group box 1 protein (HMGB1), and provides an HMGB1 binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20X21AFIYX26LED or a sequence having at least 93% identity thereto. The present disclosure also relates to the use of such an HMGB1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

公开(公告)号：US20210253659A1

公开(公告)日：2021-08-19

申请号：US17163961

申请日：2021-02-01

Applicant: AFFIBODY AB

Inventor： Fredrik Frejd ,  Joachim Feldwisch ,  Susanne Klint ,  Lindvi Gudmundsdotter

IPC: C07K14/54 ,  C07K14/745 ,  A61K38/20

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX2DX4AX6X7EIX10X11LPNL X16X17X18QX20X21AFIX25X26LX28X29. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.

公开(公告)号：US10894097B2

公开(公告)日：2021-01-19

申请号：US16145115

申请日：2018-09-27

Applicant: GENERAL ELECTRIC COMPANY ,  AFFIBODY AB

Inventor： Faisal Ahmed Syud ,  Brian Duh-Lan Lee ,  Rong Zhang ,  Peter Brian Iveson ,  Paul Schaffer ,  Tove Simonsson ,  Elin Gunneriusson ,  Fredrik Frejd ,  Lars Abrahmsen ,  Joachim Feldwisch ,  Nina Herne ,  Christofer Lendel

IPC: A61K51/08 ,  C07K14/71

Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

公开(公告)号：US10669314B2

公开(公告)日：2020-06-02

申请号：US15317188

申请日：2015-06-15

Applicant: Affibody AB

Inventor： Fredrik Frejd ,  Elin Gunneriusson ,  Ingmarie Höidén-Guthenberg ,  Per-Ake Nygren ,  Susanne Klint ,  Feifan Yu

IPC: C07K14/00 ,  G01N33/68 ,  C07K14/54 ,  A61K38/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-6, and provides an IL-6 binding polypeptide comprising the sequence EEX3X4AWX7EIH X11 LPNLX16X17X18QX20 X21AFIX25X26LX28X29. The present disclosure also relates to the use of such an IL-6 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

公开(公告)号：US10323066B2

公开(公告)日：2019-06-18

申请号：US15510900

申请日：2015-09-17

Applicant: Affibody AB

Inventor： Lars Abrahmsén ,  Caroline Ekblad ,  Elin Gunneriusson ,  Torbjörn Gräslund ,  Johan Seijsing ,  John Löfblom ,  Malin Lindborg ,  Fredrik Frejd ,  Lindvi Gudmundsdotter

IPC: C07K14/31 ,  C07K14/00 ,  C07K14/735 ,  C07K14/74 ,  A61K38/00

Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US10155792B2

公开(公告)日：2018-12-18

申请号：US14427102

申请日：2013-09-25

Applicant: AFFIBODY AB

Inventor： Caroline Ekblad ,  Joachim Feldwisch ,  Kyong-Hoon Ahn

IPC: C07K14/195 ,  A61K38/00 ,  C07K14/315 ,  A61K47/48

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. In particular, the present invention relates to albumin binding polypeptides which have a high resistance to enzymatic cleavage. The disclosure provides an albumin binding polypeptide comprising an albumin binding motif, which motif consists of the amino acid sequence GVSDFYKKLI XaKAKTVEGVE ALKXbXcI (SEQ ID NO:29).

公开(公告)号：US10118949B2

公开(公告)日：2018-11-06

申请号：US14551931

申请日：2014-11-24

Applicant: Affibody AB

Inventor： Lars Abrahmsén ,  Andreas Jonsson ,  Jakob Dogan ,  Per-Åke Nygren

IPC: C07K14/00 ,  C07K14/61 ,  C07K14/535 ,  C07K14/755 ,  C07K16/18 ,  C07K14/31 ,  C07K14/315 ,  C07K14/605 ,  A61K38/00

Abstract: The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans.